mantle cell lymphoma
Gilead’s Kite gains some height after second CAR-T approval in US
Gilead closes in on second CAR-T approval in US
EMA starts review of second CAR-T from Gilead’s Kite unit
Gilead to file new CAR-T, setting up potential mid-2020 launch
Calquence approval another win for AstraZeneca in oncology
NICE suggests interim CDF funding while further data is gathered.
Janssen’s Imbruvica runs into trouble with NICE in mantle cell lymphoma